Immunovant, Inc. Common Stock
$36.38
Market Cap
$7.51B
Shares Outstanding
206.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 21, 2019
Round Lot
100
Locale
US
Day Open
$36.75
Day High
$37.22
Day Low
$36.11
Volume
1.17M
VWAP
$36.66
Prev Close
$36.65
Transactions
--
Acc. Volume
--
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Immunovant, Inc. Common Stock (IMVT) closed the 2026-09-16 session at $36.38, down 0.74% versus the previous close (-0.27). The stock opened at $36.75 and traded between $36.11 and $37.22 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $36.66.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Immunovant, Inc. Common Stock has a market capitalization of $7.51 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. IMVT is listed on the XNAS exchange. The company employs approximately 315 people. Immunovant, Inc. Common Stock is headquartered in DURHAM, NC. The recorded listing date is 2019-06-21.
On this page you can find market IMVT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.